Sun Pharmaceutical Industries Ltd. posted a mixed fourth quarter on Thursday and announced a softer-than-expected financial year 2026 guidance. However, Citi and Macquarie maintained positive outlooks, citing long-term growth potential and ongoing investments in specialty products. Read more at: https://www.ndtvprofit.com/quarterly-earnings/sun-pharma-q4-results-review-brokerages-stay-bullish-despite-soft-fy26-guidance Copyright © NDTV Profit